SynCardia Systems

SynCardia Systems is a pioneer and the sole commercially approved provider of a temporary total artificial heart (TAH) system, a critical solution for the most severe form of heart failure. Its technology replaces both failing ventricles and valves, serving as a bridge to transplant for patients who are not candidates for left ventricular assist devices (LVADs). As a wholly owned subsidiary of Picard Medical, the company operates commercially in the U.S. and Canada, with over 2,100 implants globally, and continues to focus on expanding clinical adoption and patient mobility through its portable driver systems. The company addresses a significant unmet need within the advanced heart failure market.

Pneumatically driven, pulsatile total artificial heart system for biventricular replacement, including implantable ventricles and external portable/hospital driver units.

SynCardia holds a monopoly on FDA-approved total artificial hearts. Primary competition comes from left ventricular assist devices (LVADs) from major players like Abbott and Medtronic, which are used for unilateral failure. Long-term competitive threats include investigational continuous-flow total artificial hearts (e.g., from CARMAT or Cleveland Heart) and advancements in xenotransplantation.